Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC)

OncoImmunology

Volumn 4, Issue 9, 2015, Pages 1-3

  Adams, Sylvia ^a   Goldstein, Lori J ^b   Sparano, Joseph A ^c   Demaria, Sandra ^a   Badve, Sunil S ^d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d INDIANA UNIVERSITY   (United States)

Author keywords

Biomarker; Breast cancer; TNBC; Tumor infiltrating lymphocytes

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CELL MUTATION; DISEASE FREE SURVIVAL; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; SCORING SYSTEM; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84944452392     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.985930     Document Type: Article

References (10)

1. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014; 32 (27):2959-66; PMID:25071121
2. Denkert C. Diagnostic and therapeutic implications of tumor-infiltrating lymphocytes in breast cancer. J Clin Oncol 2013; 31:836-7; PMID:23341523; http://dx. doi.org/10.1200/JCO.2012.47.1698
3. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013; 31:860-7; PMID:23341518; http://dx.doi.org/ 10.1200/JCO.2011.41.0902
4. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A 2012; 109:2796-801; PMID:21825174; http://dx.doi.org/10.1073/pnas. 1104303108
5. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F et al. Harmonization of the evaluation of tumor infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs-working group 2014. Ann Oncol 2015; 26(2): 259-271.
6. Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, Chen K, Scheet P, Vattathil S, Liang Het al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 2014; 512:155-60; PMID: 25079324; http://dx.doi.org/10.1038/nature13600
7. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumorreactive T cells. Nat Med 2013; 19:747-52; PMID:23644516; http://dx.doi.org/10.1038/nm.3161
8. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013; 39:11-26; PMID:23890060; http:// dx.doi.org/10.1016/j.immuni.2013.07.008
9. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014; 2:361-70; PMID:24764583; http://dx.doi.org/ 10.1158/2326-6066.CIR-13-0127
10. Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, Spranger S. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol 2013 25:268-76; PMID:23579075; http://dx.doi.org/10.1016/j. coi.2013.02.009